COMING SOON: Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated, Advanced NSCLC After Progression on Osimertinib

Martin Dietrich, MD, PhD, provides a look at an upcoming program exploring key data from the phase 3 MARIPOSA-2 study in patients with EGFR-mutated advanced NSCLC.

Related Keywords

,Without Lazertinib ,Rapid Readouts ,Nsclc ,Lung Cancer ,Non Small Cell Lung Cancer ,Egfr Mutant ,Mariposa 2 ,